General Information
-
DRAMP ID
- DRAMP03560
-
Peptide Name
- CXC chemokine GRObeta [5-73] (Human, mammals, animals)
-
Source
- Homo sapiens (Human)
-
Family
- Belongs to the intercrine alpha (chemokine CxC) family
-
Gene
- CXCL2
-
Sequence
- TELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGKSN
-
Sequence Length
- 69
-
UniProt Entry
- P19875
-
Protein Existence
- Protein level
Activity Information
-
Biological Activity
- Antimicrobial, Antibacterial, Antiparasitic, Chemotactic
-
Target Organism
- No MICs found in DRAMP database
-
Hemolytic Activity
-
- No hemolysis information or data found in the reference(s) presented in this entry
-
Cytotoxicity
-
- Not included yet
-
Binding Target
- Not found
Structure Information
-
Linear/Cyclic
- Not included yet
-
N-terminal Modification
- Not included yet
-
C-terminal Modification
- Not included yet
-
Nonterminal Modifications and Unusual Amino Acids
- Not included yet
-
Stereochemistry
- Not included yet
-
Structure
- Combine helix and beta structure
-
Structure Description
- GRObeta [5-73] forms a dimer in solution that is architectured by a six-stranded antiparallel beta-sheet (residues 25 to 29, 39 to 44, 49 to 52) and a pair of helices (residues 58 to 68) with 2-fold symmetry, while the C terminus of the protein is disordered.(Ref.2)
-
Helical Wheel Diagram
-
PDB ID
- 1QNK resolved by NMR.
-
Predicted Structure
- There is no predicted structure for DRAMP03560.
Physicochemical Information
-
Formula
- C325H561N97O95S6
Absent Amino Acids
- DFWY
Common Amino Acids
- K
Mass
- 7539.98
PI
- 9.75
Basic Residues
- 13
Acidic Residues
- 3
Hydrophobic Residues
- 20
Net Charge
- +10
-
Boman Index
- -94.47
Hydrophobicity
- -0.377
Aliphatic Index
- 90.43
Half Life
-
- Mammalian:7.2 hour
- Yeast:>20 hour
- E.coli:>10 hour
Extinction Coefficient Cystines
- 250
Absorbance 280nm
- 3.68
Polar Residues
- 21
DRAMP03560
Comments Information
Function
- Produced by activated monocytes and neutrophils and expressed at sites of inflammation. Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity.
PTM
- The N-terminal processed form GRO-beta(5-73) is produced by proteolytic cleavage after secretion from bone marrow stromal cells.
Pharmaceutical use
- GRO-beta(5-73) is available under the name Garnocestim as immunomodulator. It is used prior to hematopoietic transplantation for peripheral blood stem cell mobilization and reduction of incidence, duration, and/or severity of chemotherapy induced cytopenias.
Literature Information
- ·Literature 1
-
Title
- Many chemokines including CCL20/MIP-3alpha display antimicrobial activity.
-
Pubmed ID
- 12949249
-
Reference
- J Leukoc Biol. 2003 Sep;74(3):448-455.
-
Author
- Yang D, Chen Q, Hoover DM, Staley P, Tucker KD, Lubkowski J, Oppenheim JJ.
- ·Literature 2
-
Title
- Nuclear magnetic resonance solution structure of truncated human GRObeta [5-73] and its structural comparison with CXC chemokine family members GROalpha and IL-8.
-
Pubmed ID
- 10600366
-
Reference
- J Mol Biol. 1999 Dec 17;294(5):1065-1072.
-
Author
- Qian YQ, Johanson KO, McDevitt P.